Reolysin®. Oncolytic virus

Drugs of the Future

Volumn 33, Issue 6, 2008, Pages 489-495

  Eckschlager, Tomas ^a   Figova, K ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; ONCOLYTIC VIRUS; RAS PROTEIN; REOLYSIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FLU LIKE SYNDROME; GENE ACTIVATION; GENE TARGETING; HUMAN; LEUKEMIA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; REOVIRUS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TISSUE SPECIFICITY; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR REGRESSION; VIRUS EXPRESSION; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 51749118475     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.06.1215999     Document Type: Article

References (62)

1. Bluming, A.Z., Ziegler, J.L. Regression of Burkitt'slymphoma in association with measles infection. Lancet 1971, 2(7715): 105-6.
2. Hansen, R.M., Libnoch, J.A. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 1978, 138(7): 1137-8.
3. Wein, L.M., Wu, J.T., Kim, D.H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: Implications for virus design and delivery. Cancer Res 2003, 63(6): 1317-24.
4. Ring, C.J. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002, 83(Pt. 3): 491-502.
5. Smith, E.R., Chiocca, E.A. Oncolytic viruses as novel anticancer agents: Turning one scourge against another. Expert Opin Investig Drugs 2000, 9(2): 311-27.
6. Vile, R., Ando, D., Kim, D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafely points to consider. Cancer Gene Ther 2002, 9(12): 1062-7.
7. Wildner, O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther 2003, 5(4): 351-61.
8. Todo, T., Rabkin, S.D., Chachlavi, A., Martuza, R.L. Cortico-steroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999, 10(17): 2869-78.
9. Hirasawa, K., Nishikawa, S.G., Norman, K.L. et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003, 63(2): 348-53.
10. Mullen, J.T., Tanabe, K.K. Viral oncolysis for malignant liver tumors. Ann Surg Oncol 2003, 10(6): 596-605.
11. Schulz, O., Diebold, S.S., Chen, M. et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433(7028): 887-92.
12. Coffey, M.C., Strong, J.E., Forsyth, P.A., Lee, P.W.K. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282(5392): 1332-4.
13. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., Lee, P.W. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998, 17(12): 3351-62.
14. Nibert, M.L., Schiff, L.A. Reoviruses and their replication. In: Fields Virology. B.N. Fields, D.M Knipe, P.M. Howley (Eds.). Lippincott-Raven Publisher, Philadelphia, 2001, 1679-728.
15. Tyler, K.L. Mammalian reoviruses. In: Fields Virology, B.N. Fields, D.M Knipe, P.M. Howley (Eds.). Lippincott-Raven Publisher, Philadelphia, 2001, 1729-45.
16. Jackson, G.G., Muldoon, R.L. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J Infect Dis 1973, 128(6): 811-66.
17. Minuk, G.Y., Paul, R.W., Lee, P.W. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985, 16(1): 55-60.
18. Furlong, D.B., Nibert, M.L., Fields, B.N. Sigma 1 protein of mammalian reoviruses extends from the surfaces of viral particles. J Virol 1988, 62(1): 246-56.
19. Chappell, J.D., Duong, J.L., Wright, B.W., Dermody, T.S. Identification of carbohydrate-binding domains in the attachment proteins of type 1 and type 3 reoviruses. J Virol 2000, 74(18): 8472-9.
20. Chappell, J.D., Gunn, V.L., Wetzel, J.D., Baer, G.S., Dermody, T.S. Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein σ 1. J Virol 1997, 71(3): 1834-41.
21. Barton, E.S., Forrest, J.C., Connolly, J.L. et al. Junction adhesion molecule is a receptor for reovirus. Cell 2001, 104(3): 441-51.
22. Chappell, J.D., Barton, E.S., Smith, T.H., Baer, G.S., Duong, D.T., Nibert, M.L., Dermody, T.S. Cleavage susceptibility of reovirus attachment protein σ 1 during proteolytic disassembly of virions is determined by a sequence polymorphism in the σ 1 neck. J Virol 1998, 72(10): 8205-13.
23. Barton, E.S., Connolly, J.L., Forrest, J.C., Chappell, J.D., Dermody, T.S. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem 2001, 276(3): 2200-11.
24. Connolly, J.L., Dermody, T.S. Virion disassembly is required for apoplosis induced by reovirus. J Virol 2002, 76(4): 1632-41.
25. O'Donnell, S.M., Holm, G.H., Pierce, J.M. et al. Identification of an NF-kappaB-dependent gene network in cells infected by mammalian reovirus. J Virol 2006, 80(3): 1077-86.
26. Clarke, P., Meintzer, S.M., Widmann, C., Johnson, G.L., Tyler, K. L. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun. J Virol 2001, 75(23): 11275-83.
27. Norman, K.L., Lee, P.W.K. Reovirus as a potential anticancer therapeutic. In: Replication-Competent Viruses for Cancer Therapy. P. Hernaiz Driever, S.D. Rabkin (Eds.). Karger, Basel, 2001, 81-99.
28. Tyler, K.L., Squier, M.K., Rodgers, S.E. et al. Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol 1995, 69(11): 6972-9.
29. Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D., Lee, P.W. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007, 15(8): 1522-30.
30. Smakman, N., van den Wollenberg, D.J., Borel Rinkes, I.H., Hoeben, R.C., Kranenburg, O. Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 2005, 79(23): 14981-5.
31. Norman, K.L., Lee, P.W. Not all viruses are bad guys: The case for reovirus in cancer therapy. Drug Discov Today 2005, 10(12): 847-55.
32. Tyler, K.L., Clarke, P., DeBiasi, R.L., Kominsky, D., Poggioli, G.J. Reoviruses and the host cell. Trends Microbiol 2001, 9(11): 560-4.
33. Errington, F., Steele, L., Prestwich, R. et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008, 180(9): 6018-26.
34. Errington, F., White, C.L., Twigger, K.R. et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008, Epub ahead of print.
35. Steele, T.A., Hauser, C.C. The role of interferon-alpha in a successful murine tumor therapy. Exp Biol Med 2005, 230(7): 487-93.
36. Kim, M., Egan, C., Alain, T., Urbanski, S.J., Lee, P.W., Forsyth, P.A., Johnston, R.N. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 2007, 26(28): 4124-34.
37. Shah, A.C., Benos, D., Gillespie, G.Y., Markert, J.M. Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003, 65(3): 203-26.
38. Wilcox, M.E., Yang, W., Senger, D. et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001, 93(12): 903-12.
39. Forsyth, P.A., Yang, W.Q., Senger, D. et al. Reovirus oncolysis in medulloblastoma is effective in vivo and safe in rodents and primates. Proc Am Soc Clin Oncol (ASCO) 2002, 21: Abst 289.
40. Yang, W.Q., Senger, D., Muzik, H. et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003, 63(12): 3162-72.
41. Norman, K.L., Coffey, M.C., Hirasawa, K. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002, 13(5): 641-52.
42. Yang, W.Q., Senger, D.L., Lun, X.Q. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther 2004, 11(21): 1579-89.
43. Hirasawa, K., Yoon, C., Nishikawa, S.G. et al. Reovirus therapy of metastatic cancer models in immune-competent mice. Proc Am Assoc Cancer Res (AACR) 2001, 42: Abst 2427.
44. Etoh, T., Himeno, Y., Matsumoto, T. et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003, 9(3): 1218-23.
45. Zhang, W. E., Kolb, E.A. Reolysin®, an unmodified Reovirus, has significant anti-tumor activity in childhood sarcomas. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4331.
46. Brookes, J.T., Seikaly, H., Lim, T., Wong, K.K., Harris, J.R., Moore, R.B. Reovirus salvage of squamous cell cancer-contaminated wounds. J Otolaryngol 2005, 34(1): 32-7.
47. Vidal, K., Twigger, K., White, C.L. et al. Phase I trial of intratumoral administration of reovirus type 3 (Reolysin) in combination with radiation in patients with advanced malignancies. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 3998.
48. Twigger, K., Vidal, L., White, C.L. et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008, 14(3): 912-23.
49. Lane, M.E., Fahey, J.M., Besanceney, C. et al. In vivo synergy between oncolytic reovirus and gemcitabine in ras-mutated human HCT-116 xenografts. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 4812.
50. Qiao, J., Wang, H., Kottke, T. et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008, 14(1): 259-69.
51. Alain, T., Hirasawa, K., Pon, K.J. et al. Reovirus therapy of lymphoid malignancies. Blood 2002, 100(12): 4146-53.
52. Thirukkumaran, C.M., Luider, L.M., Stewart, D.A. et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003, 102(1): 377-87.
53. Bryson, J.S., Cox, D.C. Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol Immunother 1988, 26(2): 132-8.
54. www.oncolyticsbiotech.com
55. Morris, D.G., Forsyth, P.A., Paterson, K.F. et al. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol (ASCO) 2002, 21 (Part 2): Abst 92.
56. Vidal-Boixader, L., Karavasilis, V., Beirne, D. et al. Phase I trial of intratumoral administration of reovirus type 3 with radiation in patients with advanced malignancies. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 14009.
57. Spicer, J.F., Vidal, L., Pandha, H. et al. Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3572.
58. Yap, T.A., Vidal, L., Pandha, H. et al. A phase I study of wildtype reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 348.
59. Forsyth, P.A., Roldan, G., George, D. et al. A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 1563.
60. Forsyth, P., Roldán, G., George, D. et al. Phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008, 16(3): 627-32.
61. White, C.L., Twigger, K.R., Vidal, L. et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008, Epub ahead of print.
62. Ikeda, K., Wakimoto, H., Ichikawa, T. et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000, 74(10): 4765-75.